New opportunities in immunotherapy in multiple myeloma
نویسندگان
چکیده
Immunotherapy is a rapidly developing field of multiple myeloma, disease which despite the development new drugs remains incurable. There are several antigens that being assessed in preclinical and clinical settings, but most studied all B-cell maturation antigen (BCMA). BCMA target for antibody conjugated with toxins (ADCs), bispecific engagers (BITEs), modified autologous lymphocytes (CAR-T, chimeric receptor T cells). Belantamab mafodotin (ADC, registered European Union), teclistamab (BITE) two CAR-Ts: ide-cel (Food Drug Administation-approved) cilta-cel therapies myeloma. will definitely change treatment strategy myeloma accelerate fight against
منابع مشابه
Immunotherapy in Multiple Myeloma
The treatment of multiple myeloma has evolved significantly over the past decades, spanning from alkylator-based therapy to the more recent novel therapies that include proteasome inhibition and immunomodulatory agents. The introduction of immunotherapy to the treatment landscape of multiple myeloma has led to the development of new strategies and therapies that engage the immune system to enha...
متن کاملImmunotherapy for Multiple Myeloma
1Clinic for Stem Cell Transplantation, Center of Oncology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany 2 Service d’Hématologie Clinique, Hôpital Hôtel-Dieu, CHU de Nantes, Place Alexis Ricordeau, 44093 Nantes Cedex, France 3Hematology and Bone Marrow Transplantation, Internal Medicine, Chaim Sheba Medical Center, 52621 Tel-Hashomer, Israel 4Department o...
متن کاملNew Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.
Multiple myeloma is a B-cell malignancy characterized by proliferation of monoclonal plasma cells in the bone marrow. Although new therapeutic options introduced in recent years have resulted in improved survival outcomes, multiple myeloma remains incurable for a large number of patients, and new treatment options are urgently needed. Over the last 5 years, there has been a renewed interest in ...
متن کاملImmunotherapy in Multiple Sclerosis (Ms)
Summary The immunosuppressive agent has changed the clinical course of MS. Mostly,this agent, like cyclophosphamide cyclosporine A., and X-Ray of the lymphoid organ, has a lot of side effects. It should only be used in the most severe from of MS among immunosuppressive agents, Azathioprin has been used most frequently in spite of the fact that it is not very effective compared with other immun...
متن کاملThe Role of Immunotherapy in Multiple Myeloma
Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has changed considerably over the last two decades with the introduction to the clinical practice of novel agents such as proteasome inhibitors and immunomodulatory drugs. Basic research efforts towards better understanding of normal and missing immune surveillence in myeloma have led to development...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Acta haematologica Polonica
سال: 2021
ISSN: ['0001-5814', '2300-7117']
DOI: https://doi.org/10.5603/ahp.2021.0070